Coeptis Therapeutics is a pre-revenue, preclinical-stage biopharmaceutical company developing cell-based immunotherapy platforms for cancer treatment. The company engineers immune cells — T-cells and NK cells — to more effectively target and destroy cancer, with a focus on blood cancers and solid tumors. Coeptis operates as a small holding company with six employees, managing a portfolio of licensed and co-developed technologies rather than conducting extensive in-house research. Its flagship program is the SNAP-CAR platform, a universal CAR-T cell therapy licensed from the University of Pittsburgh, designed to address solid tumors — an area where no CAR-T therapy has yet received FDA approval. Coeptis also co-developed the GEAR-NK platform with Vy-Gen, an NK cell therapy engineered to work alongside anti-CD38 antibodies in multiple myeloma treatment, and recently acquired full worldwide rights to this platform. The only programs in human clinical trials are two Phase 1 studies of DVX201, an unmodified NK cell therapy in leukemia and respiratory diseases, acquired from Deverra Therapeutics. Coeptis funds operations through equity financing and intends to monetize its pipeline through licensing, commercial partnerships, or asset divestitures — as it has no in-house manufacturing or commercial capabilities. The company also owns a recently acquired AI-powered digital marketing business. Coeptis has disclosed going concern doubt, and in April 2025, entered into a merger agreement with Z Squared that would spin out its biotech operations to existing shareholders, effectively separating the biopharma pipeline from the current public entity.